View Older Stories View More Recent Stories

Mar 16, 2021 07:08AM Global Blood Therapeutics (GBT) Expands Sickle Cell Disease Pipeline with Exclusive In-license of Two Novel Small Molecule Programs from Sanofi S.A. (SNY)
Mar 16, 2021 07:00AM GBT Expands Sickle Cell Disease Pipeline with Exclusive In-license of Two Novel Small Molecule Programs from Sanofi S.A.
Mar 8, 2021 08:00AM GBT Announces New Employment Inducement Grants
Mar 2, 2021 08:00AM GBT Opens 2021 ACCEL Grant Program, Providing up to $500,000 in Support to the Sickle Cell Disease Community
Mar 2, 2021 07:30AM GBT Announces Participation at the H.C. Wainwright Global Life Sciences Conference
Feb 24, 2021 04:05PM GBT Reports Recent Business Progress and Fourth Quarter and Full Year 2020 Financial Results
Feb 19, 2021 08:00AM GBT Announces Participation in Upcoming Investor Conferences
Feb 17, 2021 08:00AM GBT to Announce Fourth Quarter and Full Year 2020 Financial Results on Wednesday, February 24, 2021
Feb 5, 2021 08:00AM GBT Announces New Employment Inducement Grants
Feb 4, 2021 08:00AM GBT Initiates Expanded Access Protocol for Oxbryta® (voxelotor) in Pediatric Patients with Sickle Cell Disease in the United States
Jan 27, 2021 07:05AM EMA Accepts GBT's (GBT) MAA for Oxbryta (voxelotor) for the Treatment of Hemolytic Anemia in Sickle Cell Diseas
Jan 27, 2021 07:00AM European Medicines Agency Accepts GBT’s Marketing Authorization Application (MAA) for Oxbryta® (voxelotor) for the Treatment of Hemolytic Anemia in Sickle Cell Disease
Jan 27, 2021 07:00AM European Medicines Agency Accepts GBT’s Marketing Authorization Application (MAA) for Oxbryta® (voxelotor) for the Treatment of Hemolytic Anemia in Sickle Cell Disease
Jan 7, 2021 08:00AM GBT Announces New Employment Inducement Grants
Jan 5, 2021 08:00AM GBT Announces Participation at the 39th Annual J.P. Morgan Healthcare Conference
Dec 15, 2020 08:00AM GBT Announces New Employment Inducement Grants
Dec 7, 2020 08:00AM GBT Appoints Kim Smith-Whitley, M.D., to Lead Research and Development
Dec 6, 2020 10:00AM GBT Presents Data on New Sickle Cell Disease Pipeline Therapies with Best-in-Class Potential – Inclacumab and GBT021601
Dec 6, 2020 10:00AM GBT Presents New Data on the Long-Term and Real-World Use of Oxbryta® (voxelotor) Tablets in Patients with Sickle Cell Disease at 62nd ASH Annual Meeting and Exposition
Dec 2, 2020 07:00AM GBT Initiates Early Access Program for Voxelotor in Patients with Sickle Cell Disease in Europe and Other Regions Outside the United States
Dec 2, 2020 07:00AM GBT Initiates Early Access Program for Voxelotor in Patients with Sickle Cell Disease in Europe and Other Regions Outside the United States
Nov 25, 2020 08:00AM GBT Announces Participation in Upcoming Investor Conferences
Nov 13, 2020 08:00AM GBT Announces Participation at the Stifel 2020 Virtual Healthcare Conference
Nov 9, 2020 08:00AM GBT Announces New Employment Inducement Grants
Nov 5, 2020 04:05PM GBT Reports Recent Business Progress and Third Quarter 2020 Financial Results
Nov 4, 2020 03:11PM GBT Announces Upcoming Virtual Data Presentations at 62nd American Society of Hematology (ASH) Annual Meeting & Exposition
Oct 29, 2020 08:00AM GBT to Announce Third Quarter 2020 Financial Results on Thursday, November 5, 2020
Oct 26, 2020 06:00AM GBT Presents Data at 15th Annual Scientific Conference on Sickle Cell and Thalassemia
Oct 26, 2020 06:00AM GBT Presents Data at 15th Annual Scientific Conference on Sickle Cell and Thalassemia
Oct 12, 2020 08:00AM GBT Receives Rare Impact Award for Innovation from the National Organization of Rare Disorders (NORD) for Development of Oxbryta® (voxelotor) Tablets
Oct 5, 2020 08:00AM GBT Announces New Employment Inducement Grants
Sep 9, 2020 08:00AM GBT and Sickle Cell Disease Association of America to Host 9th Annual Sickle Cell Disease (SCD) Therapeutics Conference
Sep 8, 2020 04:20PM Global Blood Therapeutics (GBT), Biopharma-MEA Enter Agreement to Distribute Oxbryta in Six Middle Eastern Countries
Sep 8, 2020 04:05PM GBT and Biopharma-MEA Enter Agreement to Distribute Oxbryta® (voxelotor) in Six Middle Eastern Countries
Sep 4, 2020 08:00AM GBT Announces New Employment Inducement Grants
Sep 3, 2020 08:00AM GBT Announces Participation in Upcoming Investor Conferences
Aug 7, 2020 08:00AM GBT Announces New Employment Inducement Grants
Aug 5, 2020 04:01PM GBT Reports Recent Business Progress and Second Quarter 2020 Financial Results
Jul 30, 2020 08:00AM GBT Announces Participation in Upcoming Investor Conferences
Jul 29, 2020 08:00AM GBT to Announce Second Quarter 2020 Financial Results on Wednesday, August 5, 2020
Jul 8, 2020 08:00AM GBT Announces New Employment Inducement Grants
Jun 25, 2020 01:00PM GBT Awards $250,000 in ACCEL Grants to Advance Access to Care for People Living with Sickle Cell Disease
Jun 24, 2020 08:34AM Global Blood Therapeutics (GBT) Announces Plans to Seek Regulatory Approval for Oxbryta to Treat SCD in Europe
Jun 24, 2020 08:30AM GBT Announces Plans to Seek Regulatory Approval for Oxbryta® (voxelotor) to Treat Sickle Cell Patients in Europe
Jun 24, 2020 08:30AM GBT Announces Plans to Seek Regulatory Approval for Oxbryta® (voxelotor) to Treat Sickle Cell Patients in Europe
Jun 8, 2020 04:05PM GBT Announces Plans to Seek Expanded Labeling for Oxbryta® (voxelotor) to Treat Children Ages 4 to 11 Years with Sickle Cell Disease
Jun 3, 2020 08:00AM GBT Announces New Employment Inducement Grants
Jun 2, 2020 08:00AM GBT Announces Participation at the Goldman Sachs 41st Annual Global Healthcare Conference Webcast
May 14, 2020 09:05AM GBT Announces Upcoming Data Presentations During Virtual Edition of 25th Annual European Hematology Association Congress
May 7, 2020 08:00AM GBT Announces New Employment Inducement Grants
View More Recent Stories View Older Stories